Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 USD | +11.65% | +8.59% | +5.13% |
Apr. 29 | UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating | MT |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- MarketScreener Editorial Features